Trust linked to DENTSPLY SIRONA (XRAY) director reports 50,000-share buy

Filing Impact

(High)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

DENTSPLY SIRONA Inc. director Gregory T. Lucier reported indirect open-market purchases of the company’s common stock through a trust. On March 2 and 3, the trust bought a total of 50,000 shares at weighted average prices of $14.245 and $14.028 per share.

The trust now holds 50,000 shares, while additional indirect holdings shown include 24,901.284 shares through a family partnership and 21,000 shares in a Gregory Lucier IRA. The filing notes the trust is one where Lucier serves as trustee and beneficiary and that he disclaims beneficial ownership beyond his pecuniary interest.

Insider Trade Summary

Net Buyer: 50,000 shares ($707,379)

Net Buy 4 txns

Insider LUCIER GREGORY T

Role Director

Bought 50,000 shs ($707K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	22,445	$14.028	$315K
Purchase	Common Stock	27,555	$14.245	$393K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 50,000 shares (Indirect, By a Trust)

Footnotes (1)

By a trust of which the reporting person serves as trustee and is a beneficiary. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.22 to $14.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.975 to $14.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 07:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LUCIER GREGORY T

(Last)

(First)

(Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE

28277

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		P		27,555⁽¹⁾	A	$14.245⁽²⁾	27,555	I	By a Trust
Common Stock	03/03/2026		P		22,445⁽¹⁾	A	$14.028⁽³⁾	50,000	I	By a Trust
Common Stock								24,901.284	I	By Family Partnership
Common Stock								21,000	I	By Gregory Lucier IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. By a trust of which the reporting person serves as trustee and is a beneficiary. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.22 to $14.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.975 to $14.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

	/s/ Jessica Nielsen Causey, Attorney-in-Fact for Gregory T. Lucier	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did DENTSPLY SIRONA (XRAY) report for Gregory T. Lucier?

DENTSPLY SIRONA reported that a trust associated with director Gregory T. Lucier bought 50,000 shares of common stock in open-market transactions. The purchases occurred on March 2 and March 3 at weighted average prices of $14.245 and $14.028 per share, respectively.

At what prices were the XRAY shares purchased in Gregory Lucier’s recent Form 4?

The reported XRAY share purchases were made at weighted average prices of $14.245 and $14.028 per share. Footnotes explain that individual trades occurred within narrow price ranges around these averages, and full breakdowns are available on request from the issuer, shareholders, or SEC staff.

How many XRAY shares does the trust linked to Gregory Lucier hold after the reported transactions?

After the reported purchases, the trust linked to Gregory Lucier holds 50,000 shares of DENTSPLY SIRONA common stock. These shares are reported as indirectly owned, with Lucier serving as trustee and beneficiary, and he disclaims beneficial ownership beyond his pecuniary interest in the trust holdings.

What other indirect XRAY holdings are reported for Gregory Lucier besides the trust?

In addition to the 50,000 shares held by the trust, the Form 4 shows 24,901.284 shares held through a family partnership and 21,000 shares held in a Gregory Lucier IRA. These positions are reported as indirect ownership, reflecting different entities associated with the director.

Does Gregory Lucier fully own the XRAY shares held by the reporting trust?

The filing states the shares are held by a trust where Gregory Lucier is trustee and beneficiary, but he disclaims beneficial ownership except for his pecuniary interest. This means economic benefits may be shared with others, and he does not claim full beneficial ownership of all trust-held shares.